Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCN02-Romi: Kick and Kill Strategy for HIV
NCT02616874Phase 1Completed
- Sponsor
- IrsiCaixa
- Start
- Feb 2016
- Primary completion
- Sep 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVA.HIVconsv and romidepsin in human immunodeficiency virus infection (HIV), sponsored by IrsiCaixa. Primary endpoints: Number of participants with grade >=3 adverse events assessed by Division of AIDS (DAIDS) grading table, Number of participants with serious adverse events and 1 more. Started Feb 2016; status: completed.
02
Drugs
MVA.HIVconsvromidepsin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02616874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616874.